This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Today's Health Winners and Losers

Charles River Laboratories (CRL) shares moved higher after the company posted better-than-expected fourth-quarter earnings and in-line guidance for 2006. The company, which provides services for pharmaceutical companies, earned $50.4 million, or 69 cents a share, compared with $20.1 million, or 32 cents a share, a year earlier. Excluding items, earnings were 59 cents a share, topping Wall Street's projection by 2 cents. Revenue rose 22% to $291.2 million, surpassing analysts' target of $282.8 million.

Charles River expects 2006 earnings of $2.46 to $2.52 a share, excluding stock options expenses and one-time items. The forecast brackets analysts' mean estimate of $2.48 a share. The company's shares recently changed hands at $48.22, up $3.37, or 7.5%.

Conmed (CNMD) dropped 12% after the medical equipment supplier posted fourth-quarter results that missed forecasts and warned that first-quarter results also would be weaker than expected. The company earned $2.8 million, or 10 cents a share, on sales of $153.2 million. Excluding items, Conmed earned $5.3 million, or 18 cents a share. Analysts expected earnings of 27 cents a share and sales of $160.5 million. Results were hurt by lower-than-expected surgical procedures, foreign currency translation, and extended capital equipment purchasing decision timelines in certain markets, the company said. During the year-earlier quarter, Conmed posted adjusted earnings of $14.7 million, or 49 cents a share, on sales of $161.2 million.

For the first quarter, Conmed projects earnings of 18 cents to 22 cents a share, below analysts' prediction of 38 cents. The company forecast sales of $153 million to $158 million, compared with Wall Street's target of $162.5 million. Shares were down $2.87 to $20.79.

Shares of Chattem (CHTT) tumbled 12% after the seller of health products posted fourth-quarter earnings that were a penny short of forecasts. The company earned $2.4 million, or 12 cents a share. Excluding items, the company earned $8.6 million, or 43 cents a share. Analysts expected earnings of 44 cents a share. Sales totaled $63.9 million, just shy of analysts' projection of $63.7 million. During the year-earlier period, the company posted adjusted earnings of $7.2 million, or 35 cents a share, on sales of $60.7 million.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,424.85 +162.29 1.00%
S&P 500 1,862.31 +19.33 1.05%
NASDAQ 4,086.2250 +52.0640 1.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs